Supplementary Table 2. Medication Use for Crohn’s Disease and Ulcerative Colitis by BMI Group at 1 year follow-up a

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   |  |   |   |   |   |
|  |  | **Crohn's Disease** |
|  | Normal |  | Overweight | p | Obese | p |
| **Medication** | n (%) |  | n (%) |  | n (%) |  |
|  5-Aminosalicylate | 674 (23) |  | 77 (23) | 1 | 54 (26) | 0.31 |
|  Corticosteroid | 126 (4) |  | 11 (3) | 0.46 | 6 (3) | 0.47 |
|  Thiopurine | 775 (26) |  | 105 (31) | 0.06 | 53 (26) | 0.92 |
|  Methotrexate | 497 (17) |  | 61 (18) | 0.62 | 30 (15) | 0.45 |
|  Anti-TNFa | 1379 (47) |  | 161 (48) | 0.77 | 103 (50) | 0.42 |
|  |  |  |  |  |  |  |
|  |  | **Ulcerative Colitis** |
|  | Normal |  | Overweight | p | Obese | p |
| **Medication** | n (%) |  | n (%) |  | n (%) |  |
|  5-Aminosalicylate | 681 (62) |  | 148 (60) | 0.50 | 99 (60) | 0.66 |
|  Corticosteroid | 113 (10) |  | 30 (12) | 0.48 | 20 (12) | 0.57 |
|  Thiopurine | 266 (24) |  | 67 (27) | 0.42 | 48 (29) | 0.21 |
|  Methotrexate | 72 (7) |  | 17 (7) | 0.99 | 14 (9) | 0.46 |
|  Anti-TNFa | 282 (26) |  | 76 (31) | 0.14 | 46 (28) | 0.62 |
|   |   |  |   |   |   |   |

Footnotes:

1. 1 year follow-up refers to visit closest to 365 days (within bound of 365 days and 547 days) from diagnosis for each variable